News - Pfizer, Bristol-Myers Squibb


Popular Filters

1 to 25 of 44 results

Brazil and Mexico physicians’ preferences on anticoagulants


Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP


Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

EMA advisory committee backs addition for Eliquis SmPC

EMA advisory committee backs addition for Eliquis SmPC


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

Bristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalRegulation

FDA approves new use for Bristol-Myers/Pfizer’ Eliquis

FDA approves new use for Bristol-Myers/Pfizer’ Eliquis


The US Food and Drug Administration has approved pharma major Bristol-Myers Squibb’s supplemental New…

Bristol-Myers SquibbCardio-vascularEliquisNorth AmericaPfizerPharmaceuticalRegulationUSA

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report


German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

US FDA accepts Bristol-Myers/Pfizer' Eliquis sNDA


US pharma major Bristol-Myers Squibb (NYSE: BMY) and behemoth Pfizer (NYSE: PFE) announced that the US…

Bristol-Myers SquibbCardio-vascularEliquisNorth AmericaPfizerPharmaceuticalRegulation

New EULAR recommendations address use of synthetic and biological DMARDs


The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

IQWiG re-assessments come up with same view for saxagliptin and different for crizotinib


Under the rules of the German Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute…

AstraZenecaBristol-Myers SquibbcrizotinibDiabetesEuropeKomboglyzeOncologyOnglyzaPfizerPharmaceuticalPricingRegulationsaxagliptinXalkori

Positive results from sub-analysis of Eliquis ARISTOTLE trial


US drug major Bristol-Myers Squibb (NYSE: BMY) and partner Pfizer (NYSE: PFE) reported results from a…

Bristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalResearch

Germany's IQWiG finds considerable added benefit for Bristol-Myers/Pfizer's Eliquis


In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

Briefs: Pfizer $142 million fine upheld; Bristol-Myers shuts Amylin facility


The US Court of Appeals in Boston has upheld a $142.1 million damage award to Kaiser Foundation Health…

AmylinBristol-Myers SquibbLegalManagementMarkets & MarketingNeurontinNorth AmericaPfizerPharmaceutical

Xarelto and Eliquis set to displace current therapies in DVT/PE


Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

Negative NICE final guidance for Pierre Fabre's Javlor in bladder cancer; fast-track FAD for Eliquis


In final guidance published (January 23, 2013), UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbCardio-vascularEliquisEuropeJavlorOncologyPfizerPharmaceuticalPierre FabrePricingRegulation

US FDA finally approves Bristol-Myers/Pfizer's Eliquis for stroke prevention in AF patients


The US Food and Drug Administration on December 28 finally approved the anti-clotting drug Eliquis (apixaban),…

Bristol-Myers SquibbCardio-vascularEliquisNorth AmericaPfizerPharmaceuticalRegulation

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis


Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Bristol-Myers and Pfizer's Eliquis sees first European launch, in the UK


US drug major Bristol-Myers Squibb (NYSE: BMY) and partner global pharma behemoth Pfizer (NYSE: PFE)…

Bristol-Myers SquibbCardio-vascularEliquisEuropeMarkets & MarketingPfizerPharmaceutical

Prognosis for renal cell carcinoma market development


Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug…

Bristol-Myers SquibbGlaxoSmithKlineGlobalMarkets & MarketingnivolumabOncologyPfizerPharmaceuticalSutentVotrient

Bristol-Myers/Pfizer's Eliquis gets EU backing for stroke prevention and NVAF


US drug major Bristol-Myers Squibb (NYSE: BMY) and partner Pfizer (NYSE: PFE), the world's largest drugmaker…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

Use of low-molecular-weight heparins and vitamin K antagonists for VTE set for sharp decline as oral agents roll out


The market shares of low-molecular-weight heparins and vitamin K antagonists continue to be gradually…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalMarkets & MarketingPfizerPharmaceuticalXarelto

1 to 25 of 44 results

Back to top